GSK plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GSK research report →
Range $60 – $60
Price Chart
About the company
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally.
- CEO
- Luke Victor Miels
- IPO
- 1980
- Employees
- 66,841
- HQ
- London, GL, GB
AI snapshot
Six angles, distilled from the data.
The stock is still in a longer-term corrective regime, trading below its 200-day average of 52.32 and 50-day average of 51.34. Even so, it remains well above the 52-week low of 37.95, suggesting a recovery phase rather than a broken chart.
Wall Street is cautious but not bearish: the consensus sits at Hold, with 16 Holds, 9 Buys, and 4 Sells. The target cluster is centered near 52.45 to 53, above the current trading range, but recent calls have leaned mixed, including a downgrade to Sector Perform and several reiterations.
GSK has a strong recent beat pattern, with seven straight EPS beats before the next report. Estimates point to 1.45 EPS for the upcoming quarter, and shareholders should watch whether vaccines and specialty medicines keep supporting the earnings run.
No notable insider activity. There have been no recent transactions, so there is no discretionary buying or selling signal to read into.
Profitability is solid, with a 73.5% gross margin, 30.9% operating margin, and 14.5% net margin. Growth is mixed: revenue rose 5.3% year over year, while earnings growth was down 69.5%, and free cash flow remained strong at $8.46 billion.
GSK screens as a steadier large-cap pharma name, with a low beta of 0.29 and a valuation around 10.4 times earnings. That leaves it cheaper than many defensive healthcare peers, but the chart still needs to reclaim its longer-term moving averages to improve relative momentum.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $100.62B
- P/E
- 15.65
- Fwd P/E
- 13.99
- PEG
- 0.37
- P/S
- 2.27
- P/B
- 4.27
- EV/EBITDA
- 8.25
- Div Yield
- 3.62%
- Gross Margin
- 73.29%
- Op Margin
- 24.12%
- Net Margin
- 14.52%
- ROE
- 28.35%
- ROIC
- 16.04%
Latest fiscal year · YoY change
- Revenue
- $32.67B+4.1%
- Gross Profit
- $23.65B+5.9%
- Op Income
- $8.34B
- Net Income
- $5.72B+122.0%
- EPS
- $2.82+123.8%
- OCF Growth
- +9.0%
- FCF Growth
- +63.1%
- 52W High
- $61.70
- 52W Low
- $39.29
- 50D MA
- $51.08
- 200D MA
- $52.39
- Beta
- 0.29
- RSI (14)
- 49
- Avg Volume
- 3.60M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Gibson Energy delivered a record infrastructure quarter, stronger marketing results, and outlined rising customer demand tied to new North American egress and storage needs.· July 28, 2026
- Infrastructure adjusted EBITDA reached a record CAD 169 million, up CAD 17 million year over year and CAD 9 million above the prior record.
- Consolidated adjusted EBITDA was CAD 169 million, up CAD 22 million year over year; distributable cash flow was CAD 96 million, up CAD 15 million.
- Marketing adjusted EBITDA was CAD 15 million versus CAD 8 million last year, driven by strong refined products crack spreads and better product mix.
- Management said year-to-date marketing EBITDA was CAD 18 million and is tracking toward the upper end of the CAD 40 million full-year range.
- Chauvin Pipeline closed May 1, the Hardisty connection project is expected in 1H 2027, and Chauvin expansion FID is targeted by year-end.
Gibson reported record infrastructure adjusted EBITDA of CAD 169 million in Q2 2026, up CAD 17 million from Q2 2025 and CAD 9 million above the previous record set in Q4 2025. Consolidated adjusted EBITDA was CAD 169 million, a CAD 22 million increase year over year, and distributable cash flow was CAD 96 million, up CAD 15 million year over year. Marketing adjusted EBITDA was CAD 15 million versus CAD 8 million in Q2 2025. G&A expense was CAD 16 million, below prior guidance of CAD 17 million-CAD 18 million. At quarter end, reported net debt to adjusted EBITDA was 4.2 times and infrastructure leverage was 4.4 times; on a full 12-month Chauvin basis, leverage was 3.9 times overall and 4.1 times infrastructure-only. Management continues to expect leverage to return to the long-term target range of 3 to 3.5 times in early 2027. For marketing, management said it still expects the full-year CAD 40 million range, with results trending toward the upper end, and expects Q3 to remain strong while Q4 reflects seasonality.
Curtis Philippon framed the quarter as a sign that the macro backdrop for North American energy infrastructure has improved, with new pipeline egress and Canadian market developments creating more commercial interest. He repeatedly emphasized that Gibson’s assets are strategically positioned at critical hubs and that customer discussions have accelerated across tankage, pipelines, producer partnerships, and optimization projects. His tone was constructive and confident, but he also said it is still early for final decisions on some projects and that the DRU business may take a back seat until more clarity emerges.
Riley Hicks focused on the financial strength of the quarter: infrastructure EBITDA of CAD 169 million, marketing EBITDA of CAD 15 million, distributable cash flow of CAD 96 million, and G&A of CAD 16 million versus prior guidance of CAD 17 million-CAD 18 million. He highlighted approximately 8 million barrels of additional throughput versus last year, the benefit of Chauvin, and the company’s cost actions, including expected CAD 10 million of sustainable annualized savings in 2027. He also said leverage should return to the 3 to 3.5 times range in early 2027, noted an 88% payout ratio at quarter end, and pointed to financing flexibility from the extension of the CAD 1 billion revolver to June 2031 and the issuance of CAD 400 million of senior unsecured notes.
Analysts pressed management on whether tankage has become the highest-probability growth opportunity, and Curtis said tanks look “very promising” because more pipeline egress tends to require more storage, though he stopped short of raising the previously outlined CAD 1 billion growth-capital expectation. Questions also centered on volatile U.S. export conditions, and Curtis said the team is working more on near-term opportunities because customers are hesitant to commit long term in a volatile market; he cited five new customers using Gateway on short-term opportunities in the quarter. On marketing and guidance, Riley said the CAD 40 million range still stands, with the high end reflecting strong refined products crack spreads and weaker crude-marketing opportunities in a backwardated market, while Curtis said Q3 should remain strong but seasonality should affect Q4.
The call suggests Gibson is benefiting from a favorable mix of record infrastructure utilization, a stronger marketing environment, and new asset contributions from Chauvin. Management also sounded upbeat about customer demand tied to Canadian egress, with more tank inquiries, more commercial discussions, and additional long-term opportunities potentially emerging from pipeline and storage needs.
Management repeatedly said the environment is volatile, especially in U.S. exports, where tanker rates, vessel availability, and commodity swings can disrupt volumes and make long-term contracts harder to secure. They also acknowledged that the DRU opportunity is quieter for now, Q4 marketing will be seasonally softer, and leverage remains above target until early 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.9%
- Shares Outstanding
- 2.00B
- Float Shares
- 1.94B
of shares held by institutions
1,065 13F filers
Congressional trading
Senate and House stock disclosures for GSK, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Val HoyleHouse · OR04 | Sell | Sep 23, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Aug 4, 25 | Filing → |
| Val HoyleHouse · OR04 | Buy | Nov 18, 24 | Filing → |
| Robert AderholtHouse · AL04 | Sell | Jul 28, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 24, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Bruce WestermanHouse · AR04 | Sell | Apr 21, 25 | Filing → |
| Bruce WestermanHouse · AR04 | Buy | Mar 3, 25 | Filing → |
| Marjorie Taylor GreeneHouse · GA14 | Buy | Nov 25, 24 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Oct 16, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 64.96M | ▼ 2.70M |
| Dodge & Cox | 48.20M | ▼ 10.47M |
| Fisher Asset Management, LLC | 35.72M | ▲ 1.20M |
| Primecap Management Co | 25.18M | ▼ 22.47K |
| Wellington Management Group Llp | 11.40M | ▼ 321.36K |
| Jtc Employer Solutions Trustee Ltd | 8.59M | ▼ 449.40K |
| Morgan Stanley | 7.66M | ▼ 3.37M |
| Royal Bank Of Canada | 7.59M | ▲ 82.14K |
| Price T Rowe Associates Inc | 6.92M | ▼ 399.19K |
| Acadian Asset Management LLC | 6.66M | ▼ 5.14M |
| Goldman Sachs Group Inc | 6.37M | ▼ 3.22M |
| State Street Corp | 5.96M | ▼ 39.37K |
Held by 144 ETFs
Biggest fund positions in GSK by dollar value.
Our GSK coverage
Recent articles, reports, and earnings notes.

GlaxoSmithKline PLC ADR (GSK): Specialty Medicines Drive Growth
GSK is leaning on specialty medicines, Shingrix, and a strong HIV franchise to offset declines in legacy categories. The stock looks fairly valued with modest upside, making it more of a steady Hold than a high-conviction buy.

GSK (GSK): Specialty Medicines Drive a Re-Rating
GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.

GSK plc (GSK) drops 6.4% After Q1 Beat
GSK plc (GSK) fell after Q1 2026 results despite beating sales and profit forecasts. Investors focused on the quality of the beat, with much of the upside tied to legal settlement provisions and mixed segment trends across vaccines and medicines.
Want a deeper read on GSK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
marketbeat.com · Sep 16
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 15
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
zacks.com · Sep 15
GSK strikes up to $750 million deal for cancer-targeting drug
reuters.com · Sep 15
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
zacks.com · Sep 14
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
marketbeat.com · Sep 13
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
reuters.com · Sep 11
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
zacks.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed September 13, 2026 · Live quote · Not investment advice